Nieuws
-
Lees meer »
Omega Pharma reaches agreement to acquire an
| 15-03-2012
important portfolio of European OTC brands from GSKThe transaction will significantly strengthen Omega Pharma’s product portfolio and will create critical mass for the company in key markets including Germany, the UK, Poland and Italy.
Nazareth (Belgium) – 15 March 2012 (10:30 a.m. CET). Omega Pharma today announces that it has reached agreement to acquire the previously identified non-core OTC brands of GlaxoSmithKline (GSK) in Europe for EUR 470 million (GBP391 million) in cash. This transaction builds on the recently announced divestment by GSK of certain non-core OTC brands in the USA and Canada, the majority of which was completed at the end of January 2012.
The brands being acquired include Lactacyd, Abtei, Solpadeine, Zantac, Nytol and Beconase and generated sales of over EUR 200 million in 2011. The transaction is expected to be completed in the second quarter of 2012, subject to regulatory approvals.
As part of the agreement, Omega has also agreed to purchase the Herrenberg manufacturing site which is located in Germany and employs approximately 110 people. A number of the brands that are being acquired are manufactured at Herrenberg and it is anticipated that existing employees will transfer with the site to Omega Pharma under the provisions of German employment law.
Omega Pharma’s Chief Executive Officer, Marc Coucke commented: “We are very happy with this agreement, which testifies the mutual vision and commitment of Omega Pharma and Waterland, which recently became Omega Pharma’s equity partner. Several brands from the acquisition will become part of Omega Pharma’s top-20 brands, and all of the brands that are the subject to today’s announcement have the potential to grow within our group. The proposed transaction will also provide Omega Pharma with the required critical mass in a number of key European markets – i.e. Germany, the UK, Poland and Italy. We also look forward to welcoming the employees of the Herrenberg site, whose contribution will further strengthen the manufacturing capabilities of our group, to Omega Pharma.”
Omega Pharma is an OTC healthcare company headquartered in Nazareth (Belgium) with operations in 35 countries across Europe and selected emerging markets. Its products are sold across an extensive network of pharmacies and related retail outlets. For further information please visit www.omega-pharma.com.
GlaxoSmithKline is one of the world’s leading research-based pharmaceutical and healthcare companies. It is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
-
Lees meer »
Dutch boutique private equity firm Waterland has topped the third annual HEC-Dow Jones private equity performance ranking compiled by Professor Oliver Gottschalg of HEC Paris business school for Private Equity News.
-
Lees meer »
Waterland is Benelux Private Equity Firm of the Year 2011 by Private Equity News / Dow Jones
| 19-09-2011Waterland is Benelux Private Equity Firm of the Year 2011 by Private Equity News / Dow Jones. Private Equity News / Dow Jones commented as follows:
"The Dutch mid-market buyout firm has established a reputation as a strong performer and was ranked third in a study of the best-performing firms by business school HEC Paris. During 2010, Waterland bought direct marketing company Ranger Marketing and acquired the Benelux companies of gym company Fitness First. It also backed Waeyaert-Vermeersch Isolatie group, a Belgian distributor of insulation materials."
-
Lees meer »
Waterland Private Equity Investments B.V. ("Waterland") is pleased to announce the final closing of its fifth institutional fund, Waterland Private Equity Fund V ("WPEF V"), at €1.1 billion, just five months after its initial launch. The support of existing investors combined with significant interest from new investors, caused the fund to be well oversubscribed, surpassing its initial target of €900 million.
-
Lees meer »
Waterland investeert € 100 miljoen in Sarens
| 22-07-2011Sarens, een wereldleider op het vlak van kranenverhuur en het verplaatsen van uitzonderlijke lasten, heeft overeenstemming bereikt met Waterland om € 100 miljoen te investeren in het kapitaal van Sarens over een periode van 3 jaar. Deze middelen zullen aangewend worden om de internationale groeiplannen van Sarens verder te ondersteunen.
-
Lees meer »
HealthCity en Fitness First maken vandaag bekend tot een voorgenomen overeenkomst te zijn gekomen voor de overname van alle 45 Fitness First vestigingen in Frankrijk, Spanje en Italië. De vestigingen zijn verdeeld over 12 in Frankrijk, 16 in Spanje en 17 in Italië. Met deze voorgenomen overname wordt HealthCity binnen de fitnessbranche een Europees marktleider.
Fitness First verlegt haar focus naar ontwikkelende landen, in het bijzonder Azië. De verkoop van de vestigingen in Frankrijk, Spanje en Italië is daarmee een logisch vervolg op de verkoop in november vorig jaar van de Fitness First vestigingen in Benelux aan HealthCity.
-
Lees meer »
European policies are driving the growth of biofuels, with biomethanol holding a very competitive position in this space, a cleantech investor said.
Hans Scheepers, investment director at growth capital private equity fund Waterland Private Equity Investments, said the second generation biofuel is set to be an industry leader.In 2009, Waterland made an initial €33m investment into biomethanol technology provider BioMCN (and has since invested more than a further €17m), which is on track to build the world's largest biomass refinery. 'We recognise that the Renewable Energy Directive will lead to a huge market for biofuels in Europe,' Scheepers said.
'There are very few second generation biofuel plants producing at a commercial scale. We liked the company's competitive business and the management team.'Biomethanol is chemically identical to regular methanol and BioMCN uses renewable feedstock that is derived from organic waste materials. Waterland's focus is diverse and spread across sectors that are underpinned by key drivers such as sustainability, the aging population, outsourcing, and luxury and leisure.
'We focus on companies that have a considerable track record and proof of concept. Our capital injection generally goes towards the progression of their business strategy,' Scheepers said.Along this aim, he said he would be open to looking at a corporate partnership for BioMCN moving forward.
'Today, we are selling to both oil majors and manufacturers. We are open to a strategic partnership, if it accelerates the growth of the company.' -
Lees meer »
HealthCity neemt Fitness First Benelux over
| 03-11-2010Fitnessgroep HealthCity International heeft een overeenkomst getekend met het voornemen om de aandelen van Fitness First Limited in de ondernemingen van de Benelux over te nemen. Dat komt neer op een overname door HealthCity van de Fitness First-clubs en de werknemers in de drie landen.
Dankzij de overname breidt HealthCity International uit tot meer dan 200 clubs en wordt de keten absolute marktleider in de Benelux. HealthCity was al marktleider in Nederland en sinds kort ook in België na de overname van de 11 centra van Sportopolis drie jaar geleden en de uitbreiding van het aantal clubs sindsdien, maar HealthCity had nog geen clubs in Luxemburg.
De overname is nog niet helemaal rond, maar zou afgerond worden binnen de twee tot vier weken. Uiterlijk in december zal de overname officieel afgerond zijn en vallen alle Fitness First-clubs onder HealthCity. Of de overname gevolgen heeft voor het personeel, is niet meegedeeld.
- 1 2 3 4 Volgende »